1Laughter D, Istvan JA, Tofte SJ, et al. The pracalence of atopic dermatitis in oregon school children [ J ] . J Am Acad Dermatol, 2000, 43 (4) :649-655.
2Scarponi C, Nadelli B, Laflur DW, et al. Analysis of IFN-kappa expression in psoriasis and atopie dermatitis [ J ]. J Interferon Cytokine Res, 2006,26 (3) : 133-140.
3Baker BS. The role of microorganisms in atopic dermatitis [J] . Clim Exp Immunol, 2006, 114 (1) :1-9.
4Hironri M, Satoru H, Shinji S. Skin scratching switches imonun responses from Thl to Th2 type in epicutaneously immunized mice [J] . J Derma Sci, 2003, 32:223- 230.
5Novak N, Kwiek B, Bieber T. The mode of topical immunomo dulators in the immunological nework of a topic dermatitis [J] . Clin Demato, 2005, 30 (1) :160-164.
6Woltenberg A, Sharma S, yon Bubnoff D, et al. Topical tacrolimus (FKS06) leads to profound phenotypic and functional alterations of epidermal antigen-presentlng dendritc cell in dermatitis [ J ] . J Allergy Clin Immunol 2001, 107: 519-525.
7Panhans-Cross A, Novak N, Kraft S, et al. Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506) [ J ] . J Allergy Clin Immunol, 2001, 107:345-352.
8Soter NA, Fleischer AB Jr, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part Ⅱ, safety [J] . J Am Acad Dermatol 2001, 44: S39-46.
9Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part Ⅰ , efficacy [ J ] . J Am Acad Dermatol 2001, 44: S28-38.
10Schahner LA, Lamerson C, Sheehan MP, et al. Tacrolimus oinment 0. 03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatratrica patients: results from a randomized, double-blind, vehiclecontrolled study [J]. Pediatrics, 2005, 116 (3) : 334-342.
